EP2872483A4 - Tri-salt form of metformin - Google Patents

Tri-salt form of metformin

Info

Publication number
EP2872483A4
EP2872483A4 EP13817534.4A EP13817534A EP2872483A4 EP 2872483 A4 EP2872483 A4 EP 2872483A4 EP 13817534 A EP13817534 A EP 13817534A EP 2872483 A4 EP2872483 A4 EP 2872483A4
Authority
EP
European Patent Office
Prior art keywords
metformin
tri
salt form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13817534.4A
Other languages
German (de)
French (fr)
Other versions
EP2872483A1 (en
Inventor
Banavara L Mylari
Frank C Sciavolino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thetis Pharmaceuticals LLC
Original Assignee
Thetis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,970 external-priority patent/US8765811B2/en
Application filed by Thetis Pharmaceuticals LLC filed Critical Thetis Pharmaceuticals LLC
Publication of EP2872483A1 publication Critical patent/EP2872483A1/en
Publication of EP2872483A4 publication Critical patent/EP2872483A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP13817534.4A 2012-07-10 2013-07-10 Tri-salt form of metformin Withdrawn EP2872483A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261669763P 2012-07-10 2012-07-10
US201261670376P 2012-07-11 2012-07-11
US201261670368P 2012-07-11 2012-07-11
US13/841,970 US8765811B2 (en) 2012-07-10 2013-03-15 Tri-salt form of metformin
PCT/US2013/049984 WO2014011814A1 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Publications (2)

Publication Number Publication Date
EP2872483A1 EP2872483A1 (en) 2015-05-20
EP2872483A4 true EP2872483A4 (en) 2016-03-16

Family

ID=49916541

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13817534.4A Withdrawn EP2872483A4 (en) 2012-07-10 2013-07-10 Tri-salt form of metformin

Country Status (12)

Country Link
EP (1) EP2872483A4 (en)
JP (1) JP2015523382A (en)
KR (1) KR20150036235A (en)
CN (1) CN104684889A (en)
AU (1) AU2013290168A1 (en)
BR (1) BR112015000368A2 (en)
CA (1) CA2878819A1 (en)
IL (1) IL236613A0 (en)
IN (1) IN2015KN00076A (en)
MX (1) MX2015000408A (en)
WO (1) WO2014011814A1 (en)
ZA (1) ZA201500274B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
WO2015195491A1 (en) 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US20170119841A1 (en) * 2015-11-04 2017-05-04 Thetis Pharmaceuticals Llc Amino acid salts of unsaturated fatty acids
EP3454907B1 (en) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
US10471963B2 (en) 2017-04-07 2019-11-12 TuSimple System and method for transitioning between an autonomous and manual driving mode based on detection of a drivers capacity to control a vehicle
US10737695B2 (en) 2017-07-01 2020-08-11 Tusimple, Inc. System and method for adaptive cruise control for low speed following
CN113105367B (en) * 2021-03-30 2022-08-02 广州大学 Metformin salt and preparation method and application thereof
CN114349665B (en) * 2021-11-30 2023-06-09 潍坊博创国际生物医药研究院 Metformin pyroglutamic acid crystal and preparation method and application thereof
CN115192625A (en) * 2022-06-30 2022-10-18 山东海赜生物科技有限公司 Oral composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216335T3 (en) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company NEW METFORMIN SALTS AND PROCEDURE.
FR2774591B1 (en) * 1998-02-12 2000-05-05 Lipha PHARMACEUTICAL COMPOSITION COMPRISING THE ASSOCIATION OF METFORMIN AND FIBRATE AND THE USE THEREOF FOR THE PREPARATION OF MEDICINES FOR REDUCING HYPERGLYCEMIA
WO2002012177A1 (en) * 2000-08-03 2002-02-14 Igor Anatolievich Pomytkin Composition of metformin with succinic acid or salts thereof and method for treating diabetes
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
KR101226669B1 (en) * 2007-09-21 2013-01-25 한올바이오파마주식회사 Ｎ,Ｎ－dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
WO2009080022A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum tablet
WO2009151116A1 (en) * 2008-06-13 2009-12-17 持田製薬株式会社 Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
NZ624963A (en) * 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2013004364A (en) * 2010-10-19 2013-07-02 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies.
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) * 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2014124141A1 (en) * 2013-02-07 2014-08-14 Mylari Banavara L Metformin derivatives for treating diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2015523382A (en) 2015-08-13
KR20150036235A (en) 2015-04-07
CN104684889A (en) 2015-06-03
CA2878819A1 (en) 2014-01-16
IL236613A0 (en) 2015-02-26
EP2872483A1 (en) 2015-05-20
IN2015KN00076A (en) 2015-07-31
ZA201500274B (en) 2017-10-25
MX2015000408A (en) 2015-07-14
WO2014011814A1 (en) 2014-01-16
AU2013290168A1 (en) 2015-02-05
BR112015000368A2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
HK1201819A1 (en) Novel compounds
GB201207406D0 (en) Novel compounds
AU347535S (en) Bracelet
ZA201500274B (en) Tri-salt form of metformin
EP2922550A4 (en) Novel compounds
EP2922549A4 (en) Novel compounds
GB201212871D0 (en) Novel compounds
EP2922547A4 (en) Novel compounds
GB201209986D0 (en) Novel compounds
IL236312A0 (en) Preparation of 18f-fluciclovine
GB201222711D0 (en) Novel compounds
GB201207392D0 (en) Novel compounds
HK1214601A1 (en) New bis-iridium-complexes for manufacturing of ecl-labels ecl---
EP2892529A4 (en) Uses of (-)-perhexiline
GB201209670D0 (en) Novel compounds
GB201212816D0 (en) Novel compounds
GB201223187D0 (en) Formula 1- 2050
GB201222981D0 (en) Formula 1 -2050
GB201222964D0 (en) Formula 1 - 2050
GB201204590D0 (en) Prodrugs of thiazolamine compounds
GB201207154D0 (en) Novel form
AU346613S (en) Jewellery
GB201222419D0 (en) Novel compounds
GB201222430D0 (en) Novel compounds
GB201222433D0 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160217

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 277/08 20060101ALI20160211BHEP

Ipc: A61P 9/06 20060101ALI20160211BHEP

Ipc: C07C 279/26 20060101AFI20160211BHEP

Ipc: C07C 229/24 20060101ALI20160211BHEP

Ipc: A61K 31/155 20060101ALI20160211BHEP

Ipc: C07C 279/02 20060101ALI20160211BHEP

Ipc: A61P 9/04 20060101ALI20160211BHEP

Ipc: A61P 3/10 20060101ALI20160211BHEP

Ipc: A61K 31/205 20060101ALI20160211BHEP

Ipc: A61P 9/10 20060101ALI20160211BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201